Aside from the trials on those directly affected with covid-19, the pharmaceutical world doesn’t stop, and the need for studies with healthy volunteers continues regardless of pandemics.

Following a 3-month lockdown that was imposed on the Central European nation, this week saw the successful completion of the first bioequivalence study in the Czech Republic, and likely the first in Europe, since the outbreak began.

The study, which took place over the past two weekends, was the first following the suspension of such tests by the state drug authority back in March.

A detailed proposal, outlining world-leading techniques & meticulous safety measures to prevent risk among volunteers and medical staff was put forward by QUINTA-ANALYTICA as a solution to restarting studies, and it subsequently gained an official green light by both the Ethical Committee and Drug Authority for tests to get underway.

The success shows that responsible studies in the midst of a global pandemic are both viable, and indeed critical for the continued development of lifesaving medicines.

Quinta, as a leader in the field, offers a catalog of services spanning from conducting clinicaltrials to finding, auditing, approving and delivering APIs.

Get in touch with us to learn more.

Additional News

  • 18 March 2024

    News from our newly opened clinic in Ostrava

    Our new Clinic in Ostrava (CZ) is gaining momentum step by step; therefore, we have some interesting news for you from the center of the action.

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.